Samuel Cohen, MD
Pulmonary Disease · West Hollywood, CANPI 1366700700
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (51.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Intuitive Surgical at 59.3% of the total. Reporting peaked in 2021 at $3,613 and has fallen 94.4% since, to $201 in 2025.
Across 27 payments — averaging $215.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Pulmonx Corporation$2K
- Boehringer Ingelheim$250
- Vapotherm Inc$147
- Mallinckrodt Hospital Products Inc.$128
- Olympus America Inc.$117
- plus $194 from 3 others
What the payments were for
- Travel & lodging$1,45125%
- Food & beverage$1,35723%
- Education$3,00052%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 4 | $3,445 |
| Pulmonx Corporation | 9 | $1,527 |
| Boehringer Ingelheim | 2 | $250 |
| Vapotherm Inc | 2 | $147 |
| Mallinckrodt Hospital Products Inc. | 1 | $128 |
| Olympus America Inc. | 1 | $117 |
| Coaptech, Inc. | 4 | $103 |
| Boston Scientific | 2 | $48 |
| AbbVie | 2 | $43 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,807 in reported general payments places this provider in the 70th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $15,247 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $13,467 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $10,716 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $783 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in West Hollywood
- Paul NobleWest Hollywood$306K
- Oren FriedmanWest Hollywood$278K
- Tanzira ZamanWest Hollywood$105K
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.